

Canadian Society of Allergy and Clinical Immunology

## Annual Scientific Virtual Meeting



October 22 to 24, 2020  
*(Eastern Time)*

**FINAL PROGRAM**

**We are very pleased to host our 75<sup>th</sup> meeting of the Canadian Society of Allergy and Clinical Immunology.** The CSACI Annual Scientific Meeting (ASM) is a highly anticipated event each year and is our Society's flagship event. It serves as a chance to network with colleagues, exchange ideas, and gain knowledge, while also socializing and renewing friendships. The health and safety of our members, our patients, staff, family and friends are our highest priority.


Due to the pandemic, the CSACI Board of Directors, along with the ASM Program and CPD Committees, have made the decision to convert the ASM planned for October to a **virtual platform**.

Our program will showcase both live streaming and recorded components. By converting to a virtual meeting, we will be able to reach those who could not have attended our in-person meeting in Ottawa. Our virtual meeting will provide our delegates with exceptional CPD, as well as the ability to share scientific news and best practices together...all without leaving home. It will feature a compelling array of sessions including Virtual talks, a Pro/Con debate and interactive workshops, as well as a virtual exhibit hall, which will reach audiences across Canada, the USA and beyond.

Have a great meeting!

Dr. Harold Kim  
CSACI President

Dr. David Fischer  
2020 Program Chair



## 2020 ANNUAL SCIENTIFIC MEETING

### PLANNING COMMITTEE

Dr. Harold Kim, CSACI President  
Dr. David Fischer, 2020 ASM Chair, CPD Committee  
Dr. Tim Vander Leek, CSACI Vice President  
Dr. Anne Ellis, CSACI Treasurer, FIT Bowl Chair  
Dr. Lori Connors, CPD Committee Chair, CSACI Board

Dr. Catherine Biggs, Abstract Co-Chair  
Dr. Scott Cameron, 2020 Program Committee, CPD Com.  
Dr. Edmond Chan, CSACI Board  
Dr. Victoria Cook, 2020 Program Committee, CPD Com.  
Dr. Keelia Farrell, FIT Representative  
Dr. Charles Frankish, 2020 Program Committee, CPD Com.  
Dr. Kyla Hildebrand, CSACI Board  
Dr. Samira Jeimy, Abstract Co-Chair  
Dr. Sandy Kapur, 2020 Program Committee  
Dr. Elana Lavine, Pediatric Section Advisor  
Dr. Doug Mack, CSACI Board  
Dr. Christine McCusker, CSACI Board  
Dr. Beata Derfalvi, Immunology Section Advisor  
Dr. Andy O'Keefe, Asthma Section Advisor  
Dr. Jackie Quirt, Rhino-sinusitis Section Advisor  
Dr. Elinor Simons, Abstract Co-Chair  
Dr. Julia Upton, Anaphylaxis and Food Allergy Section Advisor  
Dr. Hari Vliagoftis, CSACI Board and Abstract Co-Chair  
Dr. Wade Watson, 2020 Program Committee, CPD Com.

Ms. Louise Tremblay, Executive Director  
Ms. Alexi Campbell, Manager  
Ms. Jasmin Lidington, Associate Executive Director

### PROGRAM OBJECTIVES

The CSACI Annual Scientific Meeting's main objective is to provide current information about the diagnosis, treatment and management for conditions related to allergy, asthma and immunology. This meeting is a setting for interdisciplinary exchange among professionals and provides an excellent opportunity for participants to interact virtually with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, techniques, therapies and diagnostic procedures in allergy, asthma and immunology.

- Maintain competence on a wide variety of up-to-date topics in Clinical Immunology and Allergy
- Discuss hot new topics (both published and un-published) that have arisen since the last CSACI meeting
- Establish a network of allergy and immunology colleagues from both community and university settings.
- Promote Clinical Immunology and Allergy as a specialty to our fellows-in-training, trainees and medical students.

### WHY YOU SHOULD ATTEND!

As the premier meeting of the allergy, asthma and immunology community, this conference provides several unique and engaging educational opportunities for the participant – you can:

- Interact virtually with an impressive faculty of Canadian and international speakers;
- Network virtually with colleagues across settings and disciplines;
- Translate scientific discoveries into your practice;
- Learn about policy issues that directly affect you;
- Raise questions, debate the issues, plan follow-up studies, and discuss results;
- Discuss your own research and observations;
- Meet virtually with poster presenters to learn about their research objectives; and
- Visit the exhibit hall featuring products and services specifically designed for professionals in allergy, asthma and immunology.

### TARGET AUDIENCE

The CSACI Annual Scientific meeting is intended for clinicians, researchers, trainees/students, and allied health professionals involved in research, treatment and management of diseases in allergy, asthma and immunology.

### EVALUATIONS

Delegates can provide feedback on Annual Meeting Sessions they attend by using the Annual Meeting app or by visiting the CSACI website.

#### CSACI Mission:

***The Canadian Society of Allergy & Clinical Immunology advances allergy, asthma, and immunology knowledge to optimize patient care across Canada.***

#### CSACI Vision:

***The leading expertise for care of people with allergic and immunologic disease.  
Striving for prevention and cure.***

## ANNUAL GENERAL MEETING

All CSACI members are invited to attend the CSACI and CAAIF AGMs

**OCTOBER 1, 2020 – 7:30 P.M. EASTERN**

**Participants will be eligible to win a prize!**

---

### ACCREDITATION - (Section 1 & Section 3)

This event is **PENDING** accredited group learning activity (**Section 1 & Section 3**) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please refer to the final program for accredited sessions.

#### ***AMA PRA Category 1 Credit™***

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credits to AMA credits can be found at:

[www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

#### ***CERTIFICATE OF ATTENDANCE***

All participating delegates will receive an email containing their “Certificate of Attendance” following the meeting.

### PROGRAM CHANGES AND CANCELLATIONS

Please note: The CSACI reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances.

## DISCLOSURE

Faculty and Moderator Disclosure:

Current CME guidelines state that participants should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty and moderators have completed conflict of interest declarations and those potential conflicts will be listed in the announced at the beginning of each session.

The intent of this disclosure requirement is not to prevent a speaker with a conflict of interest from making a presentation but to make known the relationship, in advance, to the audience. It is intended that any conflict be openly identified so that with full disclosure of the facts, attendees may form their own judgments about the presentation.

In addition, all members of the annual scientific program committee have also completed their declaration and have announced at each teleconference or meeting any financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include, but is not limited to, being a direct shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to a sponsoring organization.

## DISCLAIMER

The material presented at this meeting represents the opinion of the speakers and not the views of the CSACI. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the CSACI for reliance on any information presented during these educational activities. The CSACI does not guarantee, warrant or endorse any commercial products or services.

## VISIT OUR 2020 SPONSORS AND EXHIBITORS IN THE EXHIBIT HALL

The CSACI meeting has proven to be a great opportunity for a collegial interchange of ideas and product information between physicians and our corporate partners. The exhibiting companies and organizations will provide you with the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology.

---

## DON'T FORGET TO FOLLOW US ON TWITTER AND FACEBOOK



Use **#CSACI20** when you tweet to participate in virtual conversations & share what you're learning with your colleagues



THURSDAY, OCTOBER 22, 2020 - **EASTERN TIME**

1010-1330

**FIT SYMPOSIUM WORKSHOP, LUNCH AND ELECTIONS (CLOSED)**

0930-1010 BREAKFAST AND ORIENTATION

1010-1045 SESSION 1: TRANSITION TO PRACTICE  
MODERATORS:  
SPEAKERS: DRS. ABDURRAHMAN, VICTORIA COOK  
MICHAEL FEIN AND AUDREY SEGAL  
OBJECTIVES: By the end of this session participants will be able to:  
1. Discuss common issues in transition to practice

1045-1115 BREAK

1115-1200 SESSION 2: ORAL FOOD CHALLENGES – LIVE PANEL DISCUSSION  
SPEAKERS: DRS. RHODA KAGAN, PER LIDMAN AND GREG REX  
OBJECTIVES: By the end of this session participants will be able to:  
1. Discuss common issues in oral food challenges

1200-1230 VIRTUAL LUNCH

1230-1250 ELECTIONS

1250-1315 SESSION 3: MAST CELL DISORDERS  
SPEAKER: DR. MARIANA CASTELLS, BOSTON, MA  
OBJECTIVES: By the end of this session participants will be able to:  
1. Compare features of different mast cell disorders (clonal and non-clonal)  
2. Develop a diagnostic approach for mast cell disorders  
3. Explain the current treatment of mast cell disorders

1315-1330 DISCUSSION PERIODIIIIII

1330-1615

**IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY**

**ZOOM LINK:** [https://zoom.us/webinar/register/WN\\_jxJbq5neTjGRqCYgS8BttA](https://zoom.us/webinar/register/WN_jxJbq5neTjGRqCYgS8BttA)  
**(CLICK ON THE ZOOM LINK ABOVE TO REGISTER FOR THIS WEBINAR)**

1645-1845

NREP MEETING (CLOSED)

1900-1915

OPENING REMARKS BY DR. HAROLD KIM AND DR. DAVID FISCHER

THURSDAY, OCTOBER 22, 2020

*This dinner session was co-developed with Sanofi Genzyme and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology).*

1915-2000

MODERATORS: DR. DAVID FISCHER AND DR. PAUL KEITH

**1915-1945** SPEAKER: DR. TANYA LAIDLAW, BOSTON, MA

TOPIC: ADVANCES IN THE TREATMENT OF NASAL POLYPOSIS

OBJECTIVES: By the end of this session participants will be able to:

1. Define patient population that may benefit from treatment advances for nasal polyposis
2. Compare and contrast current standard of care for nasal polyposis with biologics

1945-2000 DISCUSSION PERIOD

FRIDAY, OCTOBER 23, 2020

*This breakfast session was co-developed with Medexus and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology).*

0900-0955

MODERATORS: DR. DOUG MACK AND DR. REBECCA PRATT

**0915-0945** – SPEAKER: DR. ZAINAB ABDURRHAMAN, TORONTO, ON

TOPIC: THE ITCH THAT NEVER RASHES: AN APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF GENERALIZED PRURITUS

**(Section 3 – Q&As must be responded to receive credits)**

OBJECTIVES: By the end of this session participants will be able to:

1. Describe the pathophysiology of pruritus
2. Summarize appropriate diagnostic evaluation for pruritus
3. Compose a treatment plan for a patient presenting with generalized pruritus (including CanMEDs Communicator role)

0945-0955 DISCUSSION PERIOD

## FRIDAY, OCTOBER 23, 2020

1000-1050

PLENARY SESSION I – FOOD ALLERGY

MODERATORS: DR. VY KIM AND DR. JULIA UPTON

**1000-1020** – SPEAKER: DR. RUCHI GUPTA, CHICAGO, ILLINOIS

TOPIC: DOES FOOD ALLERGY DISPROPORTIONATELY AFFECT PARTICULAR RACES AND ETHNICITIES?

OBJECTIVES: By the end of this session participants will be able to:

1. Summarize existing data on food allergy and race/ethnicity
2. Consider conscious and unconscious bias in management of food allergy (CanMEDs advocacy role)

**1020-1040** – SPEAKER: DR. SUSAN WASERMAN, HAMILTON, ON

TOPIC: FOOD ALLERGY IN CHILD CARE CENTERS AND SCHOOLS: DEVELOPMENT OF INTERNATIONAL GUIDELINES

OBJECTIVES: By the end of this session participants will be able to:

1. Describe the development of international guidelines for the management of food allergy in child care centers and schools
2. Discuss the risk of allergic events in child care settings and schools (CanMEDs Advocacy role)
3. Summarize evidence-based recommendations for food allergy in child care settings and schools

1040-1050 DISCUSSION PERIOD

1050-1100

**VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**

1100-1150

PLENARY SESSION II – PRACTICAL MANAGEMENT OF IMMUNE DISEASES

MODERATORS: DR. KYLA HILDEBRAND AND DR. GINA LACUESTA

**1100-1120** – SPEAKER: DR. HILARY LONGHURST, UK

TOPIC: HAE GUIDELINES DIAGNOSIS AND MANAGEMENT WITH AND WITHOUT COVID-19

OBJECTIVES: By the end of this session participants will be able to:

1. Summarize current HAE guidelines for all types of HAE
2. Explain modifications in HAE management due to COVID-19

**1120-1140** – SPEAKER: DR. ANNE PHAM-HUY, OTTAWA, ON

**NO SECTION 3 CREDITS FOR THIS SESSION**

TOPIC: TO VACCINATE OR NOT TO VACCINATE: WHAT IS ROLE FOR VACCINATION IN PRIMARY AND SECONDARY IMMUNE DEFICIENCIES

OBJECTIVES: By the end of this session participants will be able to:

1. Optimize immunization in primary and secondary immunodeficiencies
2. Specify which vaccines are contraindicated in PID and SID

1140-1150 DISCUSSION PERIOD



FRIDAY, OCTOBER 23, 2020

**1150-1210 CSACI AWARDS PRESENTATIONS AND OTHER CSACI NEWS**

*This luncheon session was co-developed with Merck and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology).*

**1210-1300** MODERATORS: DR. LORI CONNORS AND DR. TIM OLYNYCH  
**1230-1250** – SPEAKER: DR. JACLYN SMITH, MANCHESTER, UK  
TOPIC: ADVANCES IN COUGH RESEARCH

OBJECTIVES: By the end of this session participants will be able to:

1. Define chronic cough
2. Explain current diagnostic approach to chronic cough
3. Compare current treatments and new treatment advances in chronic cough

**1250-1300** DISCUSSION PERIOD

**1305-1355** KEYNOTE PRESENTATION – IMMUNOLOGY OF COVID-19  
MODERATORS: DR. DAVID FISCHER AND DR. HAROLD KIM  
**1305-1325** – SPEAKER: DR. CATHERINE BIGGS, VANCOUVER, BC  
TOPIC: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN

OBJECTIVES: By the end of this session participants will be able to:

1. Describe the clinical entity known as multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19
2. Recognize the clinical features of MIS-C
3. Compare the clinical and immunologic features of MIS-C with other infectious & inflammatory diseases of childhood

**1325-1345** – SPEAKER: DR. SCOTT HALPERIN, HALIFAX, NS  
TOPIC: THE RACE FOR A COVID-19 VACCINE

OBJECTIVES: By the end of this session participants will be able to:

1. Summarize vaccine development approach in Canada
2. Explain COVID-19 vaccine development approach

**1345-1355** DISCUSSION PERIOD

**1355-1405** VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)

FRIDAY, OCTOBER 23, 2020

1405-1455

PLENARY SESSION III – Update in Peanut/Nut Allergies

MODERATORS: DR. EDMOND CHAN AND DR. TIM VANDER LEEK

**1405-1425** – SPEAKER: DR. HELEN BROUGH, LONDON, UK

TOPIC: LESSONS LEARNED FROM THE PRO-NUTS STUDY ABOUT INTRODUCTION OF MULTIPLE NUTS AND SEEDS TO ATOPIC CHILDREN

OBJECTIVES: By the end of this session participants will be able to:

1. Summarize the lessons learned about selective nut introduction and the rate of co-existent peanut, tree nut and sesame seed allergies in the PRONUTS study
2. Compare and contrast pearls and pitfalls from the PRONUTS study

**1425-1445** – SPEAKER: DR. MARCUS SHAKER, HANOVER, NH

TOPIC: COST-EFFECTIVENESS OF PEANUT ALLERGY MANAGEMENT STRATEGIES

OBJECTIVES: By the end of this session participants will be able to:

1. Define cost-effective care, common terms and concepts related to cost-effective analysis
2. Discuss recent cost-effective evaluations of food allergy

1445-1455 DISCUSSION PERIOD

## FRIDAY, OCTOBER 23, 2020

1500-1640

### PLENARY SESSION IV – SECTION 3 WORKSHOPS (CHOOSE YOUR TIMES AND TOPICS)

1500-1530	<p><b>TITLE: ORAL IMMUNOTHERAPY PRACTICAL MANAGEMENT</b>  <b>SPEAKERS: DR. SCOTT CAMERON AND DR. VICTORIA COOK</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Perform OIT in an outpatient clinic environment</li> <li>2. Manage side effects and reactions in OIT</li> </ol>
1535-1605	
1610-1640	
1500-1530	<p><b>TITLE: SUBCUTANEOUS AND SUBLINGUAL ALLERGEN IMMUNOTHERAPY: INTERESTING CASES</b>  <b>SPEAKERS: DR. SAMIRA JEIMY AND DR. BILL MOOTE</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Manage complex SCIT/SLIT cases</li> <li>2. Obtain informed consent for SCIT/SLIT (CanMEDs Communicator role)</li> </ol>
1535-1605	
1610-1640	
1500-1530	<p><b>MANAGING PSYCHOSOCIAL ASPECTS OF ALLERGY/ IMMUNOLOGY CARE</b>  <b>SPEAKERS: DR. LORI CONNORS, DR. WADE WATSON</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Work in intra and inter-professional teams to manage complex allergy/immunology patients (CanMEDs Collaborator and Leader role)</li> <li>2. Discuss psychosocial aspects of care in allergy/immunology (CanMEDs Communicator role)</li> </ol>
1535-1605	
1610-1640	

## FRIDAY, OCTOBER 23, 2020

1500-1600

**CONCURRENT TALK – BASIC SCIENCE - "NEURO-IMMUNE INTERACTIONS IN ALLERGY"**

**MODERATOR: DR. HARISSIOS VLIAGOFTIS**

**OBJECTIVES: By the end of this session participants will be able to:**

1. Explain cross-talk between immune cells and the nervous system
2. Discuss mechanisms of neuro-immune interactions in allergy and immunology

1500-1515

**SPEAKER: DR. PAUL FORSYTH**

**TOPIC: ALLERGY AND THE MICROBIOTA-GUT-BRAIN AXIS**

1515-1520

**DISCUSSION PERIOD**

1520-1535

**SPEAKER: DR. THOMAS RITZ**

**TOPIC: BRAIN-LUNG INTERACTIONS IN ALLERGY**

1535-1540

**DISCUSSION PERIOD**

1540-1555

**SPEAKER: DR. SEBASTIEN TALBOT**

**TOPIC: LUNG NEURONS CONTROL ALLERGIC AIRWAY INFLAMMATION**

1555-1600

**DISCUSSION PERIOD**

**1600-1645**

**VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**

1650-1800

**FIT BOWL**

**MODERATORS: DR. ANNE ELLIS, DR. CHARLES FRANKISH AND DR. BILL MOOTE**

**OBJECTIVES: By the end of this session participants will be able to:**

1. Delineate interesting facts in allergy and immunology

## SATURDAY, OCTOBER 24, 2020

0830-0900 VIRTUAL YOGA SESSION

*This breakfast session was co-developed with ALK and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology).*

0900-0955 MODERATORS: DR. MARY MCHENRY AND DR. MARIE-JOSÉE FRANCOEUR  
**0925-0945** – SPEAKER: DR. ANNE ELLIS, KINGSTON, ON  
TOPIC: ADVANCES IN SLIT IN 2020

OBJECTIVES: By the end of this session participants will be able to:

1. Analyze data on safety and efficacy of SLIT
2. Discuss therapeutic advances in SLIT

0945-0955 DISCUSSION PERIOD

1000-1050 PLENARY SESSION V - ASTHMA PLENARY: GINA GUIDELINES  
MODERATORS: DR. ANDREW O'KEEFE AND DR. BAHAR TORABI  
**1000-1020** – SPEAKER: DR. DIANE LOUGHEED, KINGSTON, ON  
TOPIC: COMPARING CTS GUIDELINES TO GINA GUIDELINES  
OBJECTIVES: By the end of this session participants will be able to:

1. Summarize CTA and GINA guidelines
2. Compare and contrasts CTS guidelines with GINA guidelines

**1020-1040** – SPEAKER: DR CONNIE YANG, Vancouver, BC  
TOPIC: PEDIATRIC IMPLICATIONS OF GINA GUIDELINES  
OBJECTIVES: By the end of this session participants will be able to:

1. Explain implications on GINA guidelines on the pediatric population in Canada
2. Discuss gaps in evidence that may impact implementation of GINA guidelines in pediatrics (CanMEDs Scholar role)

1040-1050 DISCUSSION PERIOD

## SATURDAY, OCTOBER 24, 2020

**1050-1100 VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**

**1100-1210 PLENARY SESSION VI – CONCURRENT SESSIONS**

FOOD ALLERGY- OIT SESSIONS	IMMUNOLOGY SESSIONS
<p><b>1100-1120</b>  <b>MODERATORS: DR. ELISSA ABRAMS AND DR. SANDY KAPUR</b></p> <p><b>SPEAKERS: DRS. EDMOND CHAN AND PHILIPPE BÉGIN, VANCOUVER, BC AND MONTREAL, QC</b>  <b>TOPIC: NEW CANADIAN OIT GUIDELINES</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Describe Canadian OIT guidelines</li> <li>2. Evaluate guidelines and whether you will incorporate them into your practice</li> </ol>	<p><b>1100-1120</b>  <b>MODERATORS: DR. BEATA DERFALVI AND DR. CHRISTINE MCCUSKER</b>  <b>SPEAKER: DR. TROY TORGERSON</b>  <b>TOPIC: IMMUNE DYSREGULATION/ AUTOIMMUNITY IN INBORN ERRORS OF IMMUNITY</b>  <b>TOPIC: Recognizing, Diagnosing, and Treating Immune Dysregulation Disorders</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Describe the typical presentation of patients with immune dysregulation disorders</li> <li>2. Explain genetic and other approaches to diagnose immune dysregulation disorders.</li> <li>3. Describe treatment approaches for patients with immune dysregulation disorders</li> </ol>
<b>1120-1130 Discussion Period</b>	<b>1120-1130 Discussion Period</b>
<p><b>1130-1150</b>  <b>SPEAKER: DR. HAROLD KIM, KITCHENER, ON</b>  <b>TOPIC: WHAT IS THERE TO BE DONE ABOUT THE BILLING ISSUES IN OIT IN CANADA</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Compare and contrast current billing structures for OIT across Canada</li> <li>2. Advocate for improved access to OIT for patients (CanMEDs advocacy role)</li> </ol>	<p><b>1130-1150</b>  <b>SPEAKER: DR. STUART TURVEY, VANCOUVER, BC</b>  <b>TOPIC: GERMLINE CBM-OPATHIES: FROM IMMUNODEFICIENCY TO ATOPY</b>  <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Define germline CBM-opathies</li> <li>2. Discuss the growing spectrum of CBM-opathies</li> <li>3. Develop a treatment plan for patients with confirmed CBM-opathies.</li> </ol>
<b>1150-1210 DISCUSSION PERIOD</b>	<b>1150-1210 DISCUSSION PERIOD</b>

## SATURDAY, OCTOBER 24, 2020

*This luncheon session was co-developed with GlaxoSmithKline and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Society of Allergy and Clinical Immunology).*

- 1210-1300**                    **MODERATORS: DR. REZA ALIZADEFHAR AND DR. MICHAEL FEIN**  
**1220-1250**        **SPEAKER: Dr. Richard Leigh, Calgary, AB**  
**TOPIC: GINA RECOMMENDATIONS FOR BIOLOGIC ADD-ON THERAPY FOR SEVERE ASTHMA PHENOTYPES**
- OBJECTIVES: By the end of this session participants will be able to:**
1. Define of 'uncontrolled asthma', 'difficult-to-treat asthma' and 'severe asthma'
  2. Describe classes of biologics available for asthma with focus on asthma phenotyping
  3. Discuss GINA guidelines as they pertain to add-on Type 2 targeted biologics for the treatment of severe asthma
- 1250-1300**        **DISCUSSION PERIOD**
- 1300-1340**                    **PRO-CON DEBATE**  
**TOPIC: BIRT: BUDESONIDE/FORMOTEROL AS NEEDED IS A BETTER THERAPEUTIC APPROACH TO MILD ASTHMA THAN REGULAR USE OF INHALED CORTICOSTEROIDS**  
**MODERATORS: DR. ALLAN BECKER AND DR. SUSAN WASERMAN**  
**SPEAKERS:**  
**1300-1310**        **PRO: DR CHARLES CHAN, TORONTO, ON**  
**1310-1320**        **CON: DR. MEYER BALTER, TORONTO, ON**  
**OBJECTIVES: By the end of this session participants will be able to:**
1. Compare and contrast data on budesonide/formoterol as needed and regular use of inhaled corticosteroids
- 1320-1340**        **DISCUSSION PERIOD**
- 1340-1350**                    **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**
- 1350-1500**                    **ORAL ABSTRACT QUICK SNAPPERS + VIEWING TIME FOR VIRTUAL POSTERS**  
**CO-CHAIRS: DR. HARISSIOS VLIAGOFTIS, DR. ELINOR SIMONS, DR. CATHERINE BIGGS AND DR. SAMIRA JEIMY**
- 1500-1510**                    **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**

## SATURDAY, OCTOBER 24, 2020

1510-1530

PLENARY SESSION VII – ANAPHYLAXIS

MODERATORS: DR. ANNE ELLIS AND DR. PHILIPPE BÉGIN

**1510-1530** SPEAKER: DR. WALEED ALQURASHI, OTTAWA

TOPIC: MANAGEMENT OF ANAPHYLAXIS IN 2020: MAY THE TREKK BE WITH YOU!

OBJECTIVES: By the end of this session participants will be able to:

1. Outline advances in anaphylaxis management
2. Use TREKK evidence-based resources for clinical practice

**NO SECTION 3 CREDITS FOR THIS SESSION**

1530-1540 DISCUSSION PERIOD

1540-1600

CLOSING REMARKS BY DR. HAROLD KIM AND BY DR. TIM VANDER LEEK, NEW CSACI PRESIDENT